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Von Willebrand Disease
Deanna Miller, RN
Otterbein University, Westerville, Ohio
Introduction
The topic that this nurse has chosen to
investigate and present is a bleeding
condition called von Willebrand Disease
(VWD). This nurse has a child, which is a
college endurance athlete that has been
experiencing health issues such as Iron
Deficiency Anemia. When searching blood
disorders and their pathophysiology, VWD
was the one condition that became . VWD
is one of the most prevalent inherited
bleeding disorder (James, 2017). This
disorder is the result of a low levels of von
Willebrand factor (VWF). VWF is a protein
that binds to factor VIII; an essential
clotting protein and platelets in the blood
vessel walls that aids in production of a
platelet plug during the clotting process
(National Hemophilia Foundation, n.d.).
This disorder was first described in 1926 by
Erik von Willebrand. He distinguished that
it differed from hemophilia and named it
“pseudo hemophilia”.
Three main types of VWD exist, which is
based on the VWF; type 1 VWD, type 2
VWD and type 3 VWD (National Hemophilia
Foundation, n.d.). On rare incidences, a
fourth type of VWD can developed from
other medical conditions; lymphoma’s,
leukemia’s, disorder such as lupus and
certain medications (Nordqvist, 2016).
Type 1 is found in 60-80 % of individuals,
there is an insufficient amount of VWF in
the blood and symptoms are usually mild.
Type 2 is found in 15-30 % of patients and
symptoms range from mild to moderate.
Type 3 is five to ten percent of with VWD
and there is a complete deficiency of VWF.
This type displays the most severe
symptoms (Federici, 2016, p. 42). VWD
equally affects men, women and children.
According to James (2017), “90% of women
being treated at hemophilia centers in the
U.S. have VWD” (p. 21).There is also no
geographical or ethnic affiliation with VWD
(Lillecrap, 2013). Inheritance of VWD
happens by way of autosomal dominant or
autosomal recessive patterns. This
disorder is the result of a low levels of von
Willebrand factor (VWF). Chromosome 12
is the carrier of VWD. Symptoms of the
disorder vary from mild to severe. This can
make the diagnosis of VWD difficult in
individuals with mild symptoms to be
made. In many cases, individuals with mild
symptoms go undiagnosed. Type 1 VWD is
characterized by a short supply of VWF
with normal structure and function. Type
2, is broken down into four different types
according to the defect of VWF; 2A, 2B, 2M
and 2N. Type 3 there is no functioning
VWF (Swystun, James, 2016).

Pathophysiological
Processes

Signs &Symptoms

Signs and symptoms may vary person to
person depending on the level of residual
VWF activity, the classification group VWD
that the individual has and age and sex
may play a role in the severity of signs and
symptoms to some extent (Leebeek,
Eikenboom, 2016). Type one is the most
common type of VWD seen in individuals
(CDC, 2016). Signs and symptoms are
•
Nosebleeds; individuals may
experience five or more nosebleeds
in a year, that happen for no reason
without injury. They last for long
periods of time; usually more than
10 minutes and may need packing or
cauterized to cease the nosebleed.
•
Easy bruising; frequent bruising that
happens with mild trauma.
Hematomas that are diffused in a
large surface area usually larger than
the size of a quarter.
•
Heavy menstrual cycles in women;
heavy bleeding and passing of large
clots during menstrual cycles.
Women and adolescents with VWD
may notice that they are soaking
through two or more pads or
tampons in a two-hour period.
•
Mucocutaneous bleeding lasting
more than five minutes from small
lacerations. Post-surgical areas and
prolonged bleeding after childbirth.
Oozing of blood after dental work /
dental extractions.
•
In type 2N and type 3, joint bleeding
maybe a complication (Leebeek,
Eikenboom, 2016).
•
Gastrointestinal bleeding is a
possible severe clinical manifestation
that individuals may experience.

Underlying
Pathophysiology
Most commonly inheritance pattern for
VWD is autosomal dominant. Type 2A,
2N and type 3 are known to be
autosomal recessive (DeLong,
Eikenboom, 2015). The underlying
cause of VWD lies within a qualitive or
quantitative defect of the VWF protein
(DeLong, Eikenboom, 2015). “VWF is a
high-molecular-weight glycoprotein
with a key role in the first phase of
hemostasis” (Casonato, Cattini, Barbon,
Daidone, Pontara, 2015. p. 682). VWF is
located as stated above on the short
arm of chromosome 12, at the locus
12p13.3, which contains 52 exons that
range in size from 1.3kb to 40bp
(Swystun, James, 2015). Endothelial
cells and megakaryocytes play an
important role in the circulation of VWF,
along with storage of VWF multimers in
cigar-shaped vesicles known as WeibelPalade bodies (WPBs) (Delong,
Eikenboom, 2015). In type 1 VWD,
observed is a partial VWF deficiency,
with the variant location of the VWF
gene on the external loci and variant
location on exon 1-52 (pg.48). Type 2A
VWD, is characterized by decreased
VWF-platelet binding because of the
deletion of high and intermediate
molecular weight multimers (pg.51).
Type 2B, is due to gain-of-function
missense mutations within the Gplb
binding site of VWF. This causes
unplanned VWF interactions that result
in the depletion of high molecular
weight (HMW) multimers and
subsequent thrombocytopenia (pg. 51).
Type 2M VWD is due to the decreased
VWF platelet interactions, however,
multimerization is normal. Mutations
are localized to the Gplb binding site in
the A1 andA3 domain of VWF resulting
in a decrease in VWF binding to sub
endothelial collagen (pg.52). Type 2N
VWD is initially known as autosomal
Hemophilia A. These individuals
present with a low FVIII level. This type
of VWD is an, “homozygous or
compound heterozygous manner,
involving either two 2N alleles or a 2N
and a VWF null allele” (Swytun, James,
2017, p. 53). Type 3 VWD is noted as
the severe clinical phenotype with
absent VWF in the plasma, along with
very low factor VIII: C. In 80% of
patients with type 3 VWD, genetic
defects in the VWF genes are null
alleles, which gives explanation to the
absence of VWF in whole.

Underlying Patho.
Cont.’

Type 3 VWD has a heterozygous
mutational basis consisting of 80 or more
variegated mutations, which would include
VWF gene insertions, missense mutation
and partial to total VWF gene deletions
(Swystun, James, 2017).
In 35% of cases with type 1 VWD, no
identifiable VWF mutations, this leads to
looking at other identifiable VWF
mutations: One theory is the contributor to
quantitative variation of VWF and the ABO
blood group. VWF levels is noted to be
25% lower on individuals of “O” blood type
(Lillicrap, 2017). In acquired VWD, the
most common causes include: Cardiac
disorders; aortic stenosis being the most
prevalent, lymphoproliferative diseases,
hypothyroidism, drug related and systemic
lupus erythematous (Hassan et al. 2013).

•

•

•
•

•
•

Significance of
Pathophysiology
•
•

10% of women with VWD
experience a history of endometrial
hyperplasia
Of the high occurrence of women
that experience heavy menstrual
bleeding (HMB) with no explanation
has reported to range 5% to 36%
adolescents.

•

•

Women with VWD also suffer other
forms of abnormal reproductive
bleeding such as bleeding with
ovulation resulting in a hemorrhagic
ovarian cyst or peritoneal cavity
bleeding.
Antepartum bleeding, postpartum to
severe postpartum hemorrhage, and
perineal hematoma’s increased by two
to ten-fold in women with VWD (James,
2017)
A threefold increase risk of
hypothyroidism in patients with
congenital VWD (Hassan et al., 2013)
Gastrointestinal bleeding from
angiodyplasia that is most commonly
seen in elderly patients with type 2 and
3VWD
Increase risk for arthopathy and
decrease joint function resulting in
intraarticular joint bleeding.
Patients with type 3 are at greater risk
for joint bleeding which results in a
lower quality of life than those of the
general population which is associated
with bleeding phenotype
As a result of the physiologic rise in
VWF levels throughout life, patients
with type 1 may experience levels
within normal limits when they become
older.
With type 2 VWD patients, the VWF
activity remains low due to the
functional defect in the protein, which
causes an increased risk for bleeding
symptoms that could occur with
increased age.

•

•

•
•

•

•
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Figure 1.0 Illustration of VWD in an individual

•

Individual with VWD

Injury occurs, vessel
constricts

Platelets gather at the site of injury

VWF fails- there is not enough
VWF for clot formation

•

•
•
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Implications of
Nursing

Evaluating patients is to obtain a
complete family history: It is
important to know unnoticed mild
symptoms, a family history of VWD
or abnormal bleeding may not always
be apparent
Educate patients and their family
members on VWD: how to decrease
the risk of injury, steps needed to
take to ensure patient safety during
bleeding episodes. Discuss the
importance of informing all
healthcare about their diagnosis and
type of VWD disease.
Talk with the patient and family inn
regards about notifying any sports
coach about their (Nordqvist, 2016).
Be educated on resources that are
available to patients and family
members such as; Hemophilia
treatment centers, genetic
counseling, physical therapist if joint
bleeding is a complication and
hematologist
Educate patients to consult their
physicians before taking over the
counter (OTC) medications such as
Aspirin, Ibuprofen and other NSAIDS
that may hinder blood clotting
(Nordqvist, 2016 section 7).
Be familiar with VWD and the steps
to guarantee hemostasis and
decrease risk of complications
related to VWD
A Complete blood count, activated
partial thromboplastin time (aPTT),
prothrombin time (PT), fibrinogen
level and platelet counts are
important lab values that should be
observed.
Additional test VWF antigen (VWF:
Ag), VWF ristocetin cofactor (VWF:
RCO) and a factor VIII level
Treatment for VWD is based on
normalizing VWF and factor VIII
levels, this is achieved by using
medicines such as Desmopressin
(DDAVP) or infusing exogenous
coagulation factors such as high
purity factor VIII VWF. VWF-factor
VIII or VWF concertation or
tranexamic acid is used in type 3
(Leebeek, Eikenboom, 2016)
Birth control containing estrogen
can aid in HMB in women
Encourage a well-balanced healthy
diet with exercise. Advise children
with VWD to avoid contact sports
that would increase the risk of injury
(Nordqvist, 2016)

References Cont.’

Conclusion
Although VWD is the most common
inherited blood disease, many healthcare
providers are unfamiliar about the
disorder. While researching VWD, this
nurse has gain knowledge that can assist in
identifying patients that may be suffering
from VWD. This nurse sought out to
investigate a blood disorder due to a
personal affiliation with a child that were
experiencing similar signs and symptoms of
VWD. VWD is a disorder that although
complications can occur, many individuals
that suffer from VWD can lead a normal
life with the right education and resources.
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